newsfilter
← Latest News
GlobeNewswire·

Replimune Announces Pricing of $150 Million Underwritten Offering

BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL) ("Replimune"), a commercial-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today